FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit
This article was originally published in The Gray Sheet
Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.
You may also be interested in...
FDA officials could draw from $550 million of a new “Innovation Fund” to implement certain 21st Century Cures legislation device reforms, including a breakthrough device program, health IT reforms and other provisions. The latest version of the bill, which newly directs those funds to device sections, is heading to the House floor this week.
FDA Commissioner Margaret Hamburg said she will step down from the agency after six years in the post. She is being widely praised by lawmakers and industry as an effective bureaucrat who has worked to improve FDA’s regulatory processes and speed the path to market for new products.
Jesse Goodman will become director of Georgetown University’s new Center on Medical Product Access, Safety and Stewardship while Stephen Ostroff steps up as FDA’s Acting Chief Scientist.